Publication Name	World Journal of Hepatology
Manuscript ID	13317
Country	Spain

Received	2014-08-18 09:09
Peer-Review Started	2014-08-18 14:01
To Make the First Decision	2014-09-16 11:08
Return for Revision	2014-09-20 23:49
Revised	2014-10-03 05:44
Second Decision	2015-01-22 20:42
Accepted by Journal Editor-in-Chief	2015-01-23 16:32
Accepted by Executive Editor-in-Chief	2015-02-02 20:06
Articles in Press	2015-02-02 20:06
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2015-04-29 15:00
Publish the Manuscript Online	2015-05-19 17:28

ISSN	1948-5182 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Review
Article Title	Prevention of hepatocellular carcinoma by correction of metabolic abnormalities: Role of statins and metformin
Manuscript Source	Invited Manuscript
All Author List	Javier Ampuero and Manuel Romero-Gomez
Funding Agency and Grant Number
Corresponding Author	Javier Ampuero, MD, PhD, Unit for the Clinical Management of Digestive Diseases, Valme University Hospital, Avenida de Bellavista s/n, 41014 Sevilla, Spain. javi.ampuero@gmail.com
Key Words	Hepatocellular carcinoma; Metformin; Metabolic syndrome; Mammalian target of rapamycin; Statin
Core Tip	Hepatocellular carcinoma is the result of a complex process which impairs several pathways, such as RAS/RAF/mitogen-activated protein kinase kinase/extracellular-signal-regulated kinase, phosphatidylinositol-4,5-bisphosphate 3-kinase/AKT/mammalian target of rapamycin and Wnt/β-catenin signaling. Patients showing metabolic syndrome seem to have higher incidence and mortality rates from hepatocellular carcinoma than healthy subjects, especially those with type 2 diabetes mellitus and obesity. Thus, metformin and statins, both to treat features of metabolic syndrome, have been proposed to decrease the risk of hepatocellular carcinoma. Metformin (by decreasing hyperglycemia state through 5′-adenosine monophosphate-activated protein kinase pathway activation) and statins (3?hydroxy?3-methylglutaryl coenzyme A reductase inhibitors) show anti-tumoral properties modifying several steps of the crucial signaling cascades.
Publish Date	2015-05-19 17:28
Citation	Ampuero J, Romero-Gomez M. Prevention of hepatocellular carcinoma by correction of metabolic abnormalities: Role of statins and metformin. World J Hepatol 2015; 7(8): 1105-1111
URL	http://www.wjgnet.com/1948-5182/full/v7/i8/1105.htm
DOI	http://dx.doi.org/10.4254/wjh.v7.i8.1105

Full Article (PDF)	WJH-7-1105.pdf
Full Article (Word)	WJH-7-1105.doc
Manuscript File	13317-Review.doc
Answering Reviewers	13317-Answering reviewers.pdf
Conflict-of-Interest Disclosure Form	13317-Conflict-of-interest statement.pdf
Copyright License Agreement	13317-Copyright assignment.pdf
Peer-review Report	13317-Peer-review(s).pdf
Scientific Misconduct Check	13317-CrossCheck.jpg
Scientific Editor Work List	13317-Scientific editor work list.pdf